Novartis announced a pharma alliance with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention. Read the full story
Novartis announced a pharma alliance with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention. Read the full story
Bionomics has entered into an exclusive research collaboration and pharma licensing Agreement with Merck for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. Read the full story
Neurotez announced the execution of an exclusive license agreement covering its Leptin derivatives (Leptin Products), for the treatment of Alzheimer’s disease (AD) and other cognitive disorders, with GCA Therapeutics. Read the full story
A pharma alliances is created between Biogen Idec and Proteostasis Therapeutics for Alzheimer's treatment. Read the full story
iPierian announced a Series A financing round of $30 million to advance iPierian’s drug development in neurodegenerative disease as well as launch a spin-out company, True North Therapeutics. Read the full story
AstraZeneca and Tufts University's School of Medicine and Sackler School of Graduate Biomedical Sciences are becoming pharma partners. Read the full story
Elan has entered biotech deals and decides to divest ELND005 to, Speranza Therapeutics, focused on progressing the development of ELND005 (Scyllo-inositol). Read the full story
Big pharma company, Eli Lilly, pharma deals with Siemens Medical Solutions for the asset purchase of two investigational positron emission tomography tracers to be used in a diagnostic capacity for Alzheimer's disease. Read the full story
The Alzheimer's Disease Partnering provides understanding and access to the alzheimer's disease partnering deals and agreements entered into by the worlds leading healthcare companies Read the full story
DiaGenic has reported preliminary positive findings from the collaborative R&D project with Pfizer Inc. where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring of Alzheimer’s Disease (AD). Read the full story